Drug Profile

Amenamevir - Maruho

Alternative Names: Amenalief; ASP-2151; M-5220; M5220B

Latest Information Update: 03 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma
Developer Astellas Pharma; Maruho
Class Amides; Antivirals; Oxadiazoles; Small molecules
Mechanism of Action DNA helicase-primase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Herpes simplex virus infections; Herpes zoster
No development reported Herpes labialis

Most Recent Events

03 Feb 2026 Launched for Herpes simplex virus infections in Japan (PO), prior to February 2026
03 Feb 2026 No development reported - Phase-III for Herpes labialis in Japan (PO) (Maruho pipeline, February 2026)
24 Feb 2023 Registered for Herpes simplex virus infections in Japan (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com